Home / Intelligence / Webinars / HTA Vision—Implications Beyond the Rating
Available On Demand
A number of critical manufacturer activities are informed by understanding health technology assessment (HTA) agency behavior across geographies and therapeutic areas—from pipeline, business development and licensing to launch planning preparation through to lifecycle management strategy. Join Max Hunt, a Partner in Trinity Life Sciences’ Evidence, Value, Access & Pricing Practice, as he hosts a lively discussion on the benefits of rapid access to cumulative, compounded learnings generated from in-depth analysis of global HTA recommendations, with presenters Mary Fletcher-Louis, Managing Director & Head of Trinity’s Value Center of Excellence and Andreia Ribeiro, Associate Principal.
Key Webinar Topics
- Evidence and endpoint expectations for global HTA authorities
- Population and subgroup strategies from products in the market today
- Performance thresholds by disease areas to inform future new product expectations
- In- and cross-country decision trends and time to reimbursement to help predict agencies’ behavior and optimize evidence generation plans
Featuring
Max Hunt
Partner,
Value, Access & Pricing
Mary Fletcher-Louis
Managing Director &
Head of Value Center of Excellence
Andreia Ribeiro
Associate Principal,
Value, Access & Pricing
Complete the form below to view the on-demand webinar:
By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.
This webinar will be hosted within the ON24 platform, which requires the usage of Javascript and Cookies. Please see ON24’s Privacy Policy for more information.
Related Intelligence
Blog
Seizing the Storm: Why Pharma Must Plan, Not Panic in Trump’s Second Term
The first 100 days of President Trump’s return to the White House have been anything but ordinary. With a true “Flood the Zone” strategy, there has been a flurry of executive orders, leadership reshuffles, and a re-assertion of executive power, which has signaled the administration is interested in seeing what policy options can “stick.” While […]
Read More
Webinars
The NRDL Conundrum: Balancing Between Access and Pricing for Innovation
Available On Demand
What key insights emerged from the 2024 China National Reimbursement Drug List (NRDL) negotiations and how can they inform strategic go-to-market planning for innovative therapies? In the 2024 NRDL negotiations, only 28% of submitted products passed expert review, significantly raising the bar for entering pricing negotiations.
Watch Now
Webinars
Health Equity in HTA Outcomes: Navigating the New Frontier
Available On Demand
Join Value, Access and Pricing experts as they delve into the emerging role of health equity considerations as a differentiator in value narratives for global HTA (Health Technology Assessment) submissions. NICE’s proposed methods update focused on manufacturer-submitted evidence on health inequalities.
Watch Now